Antidote-mediated control of an anticoagulant aptamer in vivo

被引:272
|
作者
Rusconi, CP
Roberts, JD
Pitoc, GA
Nimjee, SM
White, RR
Quick, G
Scardino, E
Fay, WP
Sullenger, BA
机构
[1] Duke Univ, Med Ctr, Dept Surg, Ctr Translat Res, Durham, NC 27710 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nbt1023
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote control is the safest way to regulate drug activity, because unlike rapidly clearing drugs, control of the drug activity is independent of underlying patient physiology and co-morbidities. Until recently, however, there was no general method to discover antidote-controlled drugs. Here we demonstrate that the activity and side effects of a specific class of drugs, called aptamers, can be controlled by matched antidotes in vivo. The drug, an anticoagulant aptamer, systemically induces anticoagulation in pigs and inhibits thrombosis in murine models. The antidote rapidly reverses anticoagulation engendered by the drug, and prevents drug-induced bleeding in surgically challenged animals. These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals.
引用
收藏
页码:1423 / 1428
页数:6
相关论文
共 50 条
  • [31] Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote
    Tabuchi, Yudai
    Yang, Jay
    Taki, Masumi
    CHEMICAL COMMUNICATIONS, 2021, 57 (20) : 2483 - 2486
  • [32] Aptamer to factor IXa and its matched antidote in cardiopulmonary bypass: An alternative to heparin and protamine
    Nimjee, SM
    Keys, JR
    Pitoc, GA
    Quick, G
    Rusconi, CP
    Sullenger, BA
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : E7 - E7
  • [33] How to Distribute Antidote to Control Epidemics
    Borgs, Christian
    Chayes, Jennifer
    Ganesh, Ayalvadi
    Saberi, Amin
    RANDOM STRUCTURES & ALGORITHMS, 2010, 37 (02) : 204 - 222
  • [34] Reversal of Anticoagulant-induced Bleeding in External and Internal Bleeding Models by PER977, a Small Molecule Anticoagulant Antidote
    Bakhru, Sasha
    Laulicht, Bryan
    Jiang, Xuan
    Chen, Lirong
    Grosso, Michael
    Morishima, Yoshiyuki
    Brown, Karen
    Mercuri, Michele
    Masumoto, Hiroshi
    Costin, James
    Steiner, Solomon
    CIRCULATION, 2014, 130
  • [35] Reversal of Dabigatran's Anticoagulant Activity in the Monkey by a Specific Antidote and Pharmacokinetic and Pharmacodynamic Modeling
    Toth, Joshuaine
    Gan, Guanfa
    Van Ryn, Joanne
    Dursema, Holly
    Isler, Jennifer
    Coble, Kelly
    Burke, John
    Lalovic, Bojan
    Olson, Stephen
    STROKE, 2013, 44 (02)
  • [36] Reversal of Dabigatran's Anticoagulant Activity in the Monkey by a Specific Antidote and Pharmacokinetic and Pharmacodynamic Modeling
    Toth, Joshuaine
    Gan, Guanfa
    van Ryn, Joanne
    Dursema, Holly
    Isler, Jennifer
    Coble, Kelly
    Burke, John
    Lalovic, Bojan
    Olson, Stephen
    BLOOD, 2012, 120 (21)
  • [37] Novel Modular DNA Aptamer for Human Thrombin with High Anticoagulant Activity
    Zavyalova, E.
    Golovin, A.
    Reshetnikov, R.
    Mudrik, N.
    Panteleyev, D.
    Pavlova, G.
    Kopylov, A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (22) : 3343 - 3350
  • [38] Modular design of DNA aptamer for human thrombin with high anticoagulant activity
    Kopylov, A.
    Golovin, A.
    Reshetnikov, R.
    Zavyalova, E.
    Panteleyev, D.
    Pavlova, G.
    Mudrik, N.
    FEBS JOURNAL, 2011, 278 : 158 - 158
  • [39] Aptamer mediated niosomal drug delivery
    Seleci, Didem Ag
    Seleci, Muharrem
    Jochums, Andre
    Walter, Johanna-Gabriela
    Stahl, Frank
    Scheper, Thomas
    RSC ADVANCES, 2016, 6 (91) : 87910 - 87918